The treatment of amyloidosis often involves autologous hematopoietic cell transplantation (AHCT) following high-dose melphalan. 1, 2 There has been an increasing interest in using induction chemotherapy to cyto-reduce and achieve good hematologic and organ responses prior to AHCT in amyloidosis. 3, 4 Bortezomib is a proteasome inhibitor with activity in plasma cell disorders that has been reported to achieve high rates of hematologic and organ response in amyloidosis. 5, 6 Treatment with bortezomib pre-AHCT has been shown to improve transplant eligibility for patients, previously considered to be too high risk for AHCT, and may increase the response rates following AHCT.
7-10 Herein, we describe our experience using bortezomib prior to AHCT and demonstrate the feasibility of this approach.
Twenty-four consecutive patients with primary amyloidosis underwent AHCT between June 2007 and March 2014 at our institution. Among these, 20 received induction therapy with a bortezomib-based regimen prior to transplantation. Data for these patients were obtained from our Institutional Unified Transplant Database, that prospectively collects disease and outcome data for hematopoietic cell transplantation recipients. Data were supplemented from a chart review of our institutional electronic medical records. The study was approved by the Cleveland Clinic's Institutional Review Board.
Chemotherapy prior to AHCT generally consisted of SC bortezomib 1.3 mg/m 2 and dexamethasone 40 mg weekly for 4 weeks in a 28-day cycle (Bor-Dex; N = 14 patients). For six patients cyclophosphamide 300 mg/m 2 orally or IV weekly was added to this regimen (CyBorD).
Primary amyloidosis diagnosis and organ involvement were based on the 10th International Symposium on Amyloid and Amyloidosis consensus criteria. 11 Mayo Clinic criteria were used to stage cardiac involvement. 12 Hematologic, cardiac and renal responses were categorized according to the established criteria. 7, 13, 14 The hematologic response was the primary outcome of our study, unless no hematologic involvement was present at diagnosis. Toxicity to chemotherapy was assessed retrospectively and graded according to the Common Terminology Criteria for Adverse Events, version 4.0.
AHCT was performed using melphalan conditioning (200 mg/m 2 ) given on day − 2, followed by infusion of autologous PBSC on day 0. Dose reduction was allowed for patients with severe renal dysfunction at the time of transplantation at the discretion of the treating physician. Stem cell mobilization was performed with granulocyte-CSF (G-CSF) with or without plerixafor. One patient received a planned tandem AHCT on an institutional standard-of-care protocol for plasma cell disorders. Standard institutional protocols were followed for supportive care and antimicrobial prophylaxis.
This study was a single-center, retrospective cohort study that was designed to assess the toxicity and outcomes associated with the use of pre-AHCT bortezomib-based chemotherapy. Outcomes assessed included overall survival (OS), hematologic and organ responses, toxicity and PFS. OS and PFS were measured from the date of AHCT by the Kaplan-Meier method. Given the small number of patients, we report the descriptive statistics from our study; no multivariable analyses were performed. Data were analyzed using SAS (SAS Institute, Cary, NC, USA) software. The characteristics of 20 patients are described in Table 1 . The median age of our cohort was 60 years. The median number of organs involved was two and the majority of patients (85%) had involvement of two or more organs. Eighteen (90%) patients had hematologic involvement. Among these patients, 16% had kappa light-chain and 84% had lambda light-chain amyloidosis; 50% did not have a detectable M-protein on serum or urine electrophoresis or immunofixation. Two patients did not have dFLC 450 at diagnosis; both had renal amyloidosis documented on renal biopsy. The kidney was involved in 18 (90%) patients. Three patients had severe renal dysfunction at diagnosis (estimated glomerular filtration rate o30 mL/min/1.73 m 2 ), although no patient needed dialysis. Eleven (55%) patients had significant proteinuria (44 g/24 h). At diagnosis, the median β2-microglobulin level was 2.8 mcg/mL (N = 17, range 1.4-13.5 mcg/mL). The median percentage of clonal plasma cells in the bone marrow was 5% (N = 19, range, 0-15%). Only 10% of patients had Mayo stage III-IV cardiac involvement in our series. Two patients had elevated cardiac tropnin (cTn) levels at 0.03 and 0.04 ng/mL, and the median N-terminal of the prohormone brain natriuretic peptide (NT-pro-BNP) level at diagnosis was 213 ng/L (N = 13, range, 60-8808 ng/L).
Among the 18 patients with measurable hematologic disease, 75% were transplanted in first hematologic response (CR 25%, very good partial response (VGPR) 40% and PR 10%). No patient had documented progression with any induction therapy. The two patients with Mayo stage III-IV cardiac involvement at diagnosis were treated with Bor-Dex and achieved hematologic CR and PR prior to AHCT. The bortezomib-based induction regimens were associated with the following grade 1-2 toxicities: leg edema in eight (40%) patients, peripheral neuropathy in five (25%) patients, dyspepsia/nausea/vomiting in three (15%) patients and fatigue in two (10%) patients. There were no grade 3-4 adverse events in our cohort.
The median time from diagnosis to transplant was 9 months (range 4-166 months, Table 1 ). Patients were mobilized with G-CSF with (20%) or without plerixafor (80%). For the preparative regimen, 7 (35%) patients received full-dose melphalan (200 mg/m 2 ), 12 (60%) patients received reduced-dose melphalan (140 mg/m 2 ), and 1 patient received a tandem transplant with melphalan (100 mg/m 2 ) for each AHCT. The median cell dose was 5.5 × 10 6 CD34+ cells/kg (range, 2.9-9.9). The median time to neutrophil engraftment was 11 days (range, 10-12) post AHCT. Platelet recovery X20 000/μL occurred at a median of 16 days (range, 10-27) after stem cell infusion. Nine patients received post-AHCT maintenance therapy with bortezomib, mainly in the earlier time period of our cohort.
Response was evaluated in 19 patients after excluding one patient who was followed long-term outside our institution. Among patients with measurable hematologic disease, 16/18 (89%) demonstrated response after AHCT (CR = 10, VGPR = 6). These included six patients who had achieved only PR to induction therapy and 1 patient with stable disease prior to transplantation. Renal response was observed in 13/18 (72%) patients with renal involvement. Two patients had no response but maintained stable kidney function post AHCT. Three patients had progression in renal amyloidosis; one patient developed renal failure during engraftment but recovered renal function before ultimately experiencing renal and intestinal progression, one patient died at 4 months post transplant with progressive renal failure and one patient had no response but received a renal transplant at 36 months after AHCT as there was no clinical evidence of amyloidosis elsewhere. Of the two patients with Mayo III/IV cardiac staging at diagnosis, one patient had cardiac progression at 20 months posttransplant. The second patient had concomitant renal involvement and died of progressive renal failure at 4 months post AHCT.
No patient died within the first 100 days after transplantation. Grade 3-4 adverse events in the first 6 weeks after AHCT were reported in ten patients (50%). The most commonly described non-hematologic adverse events were mucositis (five patients, 25%) and infection (five patients, 25%). Three patients with known Table 2 . Summary of studies of bortezomib-based induction treatment prior to AHCT Sanchorawala et al. 6 Cornell et al. 8 Scott et al. 9 Huang et al.
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Current study Abbreviations: AHCT = autologous hematopoietic cell transplant; Bor-Dex = bortezomib + dexamethasone; CyBorD = cyclophosphamide + bortezomib + dexamethasone; ORR = overall response rate; OS = overall survival; TRM = treatment related mortality; VGPR = very good partial response.
Letter to the Editor renal involvement required hemodialysis in the early post-AHCT period due to acute renal failure; two patients were able to discontinue dialysis at 2 and 6 months, respectively, while the third patient required ongoing dialysis and died of disease progression at 4 months. Three patients (15%) experienced nausea, vomiting and diarrhea. Two patients each (10%) experienced atrial fibrillation, thromboembolism and fluid accumulation, which were medically managed. One patient died of non-relapse cause (stroke, 33.6 months post AHCT). Overall, three patients died of disease progression. The median follow-up of survivors was 32 months (range, 11-67). OS at 5 years was 80% (95% CI, 47-94%) for the 20 patients in our cohort. PFS at 5 years for the 19 patients in whom disease status could be evaluated was 69% (95% CI, 38-86%).
We demonstrate the safety and feasibility of using bortezomib-based induction therapy prior to AHCT in patients with primary amyloidosis. Both Bor-Dex and CyBorD regimens were well tolerated, were not associated with severe toxicity, had no impact on the ability to proceed with or tolerate transplantation, and did not lead to a higher than expected rate of treatment-related mortality (TRM). The majority of patients were able to achieve a hematologic CR/VGPR to bortezomib-based induction therapy.
There has been recent interest in using bortezomib-based induction followed by AHCT in patients with primary amyloidosis (Table 2) . [8] [9] [10] 15 Overall, the collective experience of bortezomibbased induction prior to AHCT shows that it is a feasible approach for most patients who are otherwise candidates for transplantation and leads to favorable long-term outcomes.
The results of the current study are limited by its retrospective nature and the small number of patients included. We also acknowledge the heterogeneity of pre-transplant induction regimens with respect to the agents combined with bortezomib and the total number of cycles received. However, patients received a consistent transplant regimen and post-transplantation supportive care. In conclusion, bortezomib-based induction is well tolerated prior to transplantation, and further exploration of this strategy for the treatment of primary amyloidosis is warranted in prospective clinical trials.
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